Vandria
Vandria is a biopharmaceutical company that develops best-in-class small molecule mitophagy inducers to treat age-related and chronic diseases in the fields of Muscle- and CNS diseases with large unmet medical need.
Vandria has raised €28M across 1 funding round from 3 investors, most recently a Series A round in Aug 2024. Based in Lausanne, Switzerland; active in Healthtech. Data as of 28 Oct 2026.
Lausanne, Switzerlandvandria.com ↗
Total raised
€28M
€27,617,848
Funding rounds
1
Investors
3
distinct backers
Active since
2024-08
latest 2024-08
Funding by year
EUR raised per yearVandria — funding by year — interactive chart.
Data table
| Vandria — funding by year | |
|---|---|
| 2024 | €28M |
Signals
High confidenceRaise-next likelihood45
base rate 44% for Series A
- ▲ In typical raise window
- ▼ Low backer re-investment
Timing: in window vs cohort gap · momentum unknown. Funding-only estimates, not predictions and not investment advice — see signals.
Funding rounds
1 round| Date | Stage | Amount | Investors | |
|---|---|---|---|---|
| 2024-08-21 | Series A | €28M | Dolby Family Ventures,Hevolution Foundation,ND Capital | View deal → |
Related news
Similar companies
same sector or country- Philips€2.6BNetherlands · Healthtech
- Isomorphic Labs€2.3BUK · Healthtech
- CMR Surgical€1.5BUK · Healthtech
- Roivant Sciences€1.1BSwitzerland · Healthtech
- Neko Health€924MSweden · Healthtech
- Climeworks€919MSwitzerland · Cleantech
Global coverage: FundingData